Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Haemonetics Corporation for the quarter ended September 28, 1996. The company is incorporated in Massachusetts and operates in the medical technology sector, specifically focusing on blood management systems, including disposables and equipment for surgical and commercial plasma markets.
Key Financial Metrics
| Metric | Three Months Ended Sep 28, 1996 | Six Months Ended Sep 28, 1996 |
|---|---|---|
| Net Revenues | $74.4 million | $149.9 million |
| Gross Profit | $39.9 million | $82.2 million |
| Gross Margin | 53.6% | 54.8% |
| Operating Income | $12.9 million | $27.0 million |
| Net Income | $8.6 million | $18.1 million |
| Diluted EPS | $0.31 | $0.65 |
| Cash from Operations (6mo) | $8.8 million | |
| Total Debt (Current + Long-term) | $22.6 million | |
| Working Capital | $114.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8% year-over-year for the quarter and 9% for the six-month period. This was driven by a 7% increase in worldwide disposable sales (international growth) and a 15% (quarter) to 22% (six-month) increase in equipment sales (domestic growth).
- Margin Compression: Gross margin decreased to 53.6% from 55.8% in the prior year quarter. Management attributes this to a product mix shift from higher-margin surgical products to lower-margin commercial plasma products and increased spending to fund new business startups.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to 30.0% of revenues (from 29.3%) due to increased staffing and costs associated with new business opportunities.
- Debt Reduction: Total debt decreased by $6.2 million compared to the prior year, resulting in lower interest expense.
Outlook, Risks, and Management Commentary
- Liquidity: The company generated $8.8 million in operating cash flow for the six-month period, a decrease from $25.2 million in the prior year. This reduction was primarily due to increased cash utilization for accounts receivable and sales-type leases ($14.7 million) and capital expenditures ($15.9 million) related to the U.S. commercial plasma business.
- Capital Needs: Management believes committed bank lines and internally generated funds are sufficient to meet future liquidity needs. The company utilized $7.6 million from revolving credit agreements during the period.
- Foreign Exchange: The company hedges foreign currency risk with forward contracts totaling $121.6 million. Net unrealized gains on these hedges were $3.0 million as of September 28, 1996.
- Tax Rate: The provision for income taxes remained constant at approximately 35% of pretax income.
Investor Verification Checklist
- Product Mix Impact: Verify the sustainability of the shift toward lower-margin commercial plasma products and its long-term effect on gross margins.
- Capital Expenditure ROI: Assess the return on the $15.9 million in capital expenditures made for the U.S. commercial plasma business.
- Cash Flow Trends: Monitor the significant decline in operating cash flow ($25.2M to $8.8M) to ensure it is not a structural issue but rather a result of working capital buildup.
- Debt Utilization: Confirm the company's ability to service debt while maintaining the $7.6 million draw on revolving credit lines.